Insulet (PODD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 25.7% year-over-year to $543.9M, driven by Omnipod product sales in both U.S. and international markets, with Omnipod 5 launches and expanded FDA clearance for type 2 diabetes supporting growth.

• U.S. Omnipod revenue reached $395.6M (up 23.4%), International Omnipod revenue was $138.0M (up 36.1%), and Omnipod 5 became the leading insulin pump for new users in Europe.

• Gross margin improved to 69.3% (up 150 bps), operating margin rose to 16.2% (up 350 bps), and net income increased to $77.5M.

• Full market release of Omnipod 5 App for iPhone and grand opening of a new manufacturing facility in Malaysia enhanced flexibility and scale.

• Strategic decision to discontinue Omnipod GO resulted in a $13.5M inventory charge.

Financial highlights

• Q3 2024 total revenue: $543.9M, up 25.7% year-over-year; Omnipod revenue: $533.6M, up 26.4%.

• Gross margin reached 69.3%, up 150 bps year-over-year; operating margin was 16.2%, up 350 bps.

• Adjusted EBITDA for Q3 2024 was $126.1M (23.2% of revenue), up from $82.8M (19.1%).

• Net income for Q3 2024 was $77.5M; basic EPS $1.11, diluted EPS $1.08.

• Cash and cash equivalents increased to $902.6M as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue growth guidance raised to 20%-21%, with Omnipod expected to grow 21%-22%.

• U.S. Omnipod guidance at 19%-21%, International Omnipod at 25%-27%, Drug Delivery at (10)% to (5)%.

• Q4 2024 revenue growth expected at 12%-15%; gross margin for 2024 now expected at ~69%; operating margin guidance raised to ~14.5%.

• Guidance excludes $30–40M in Q4'23 U.S. Omnipod stocking dynamics for normalized growth rates.

• Drug Delivery revenue expected to remain flat year-over-year.